Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the third interim analysis of opal balance, an open-label, long-term extension study. BMJ Publishing Group Limited.

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.

Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.